Home » Stocks » SGTX

Sigilon Therapeutics, Inc. (SGTX)

Stock Price: $15.47 USD -0.17 (-1.09%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 111.84M
Revenue (ttm) 13.37M
Net Income (ttm) -54.61M
Shares Out 7.23M
EPS (ttm) -7.55
PE Ratio n/a
Forward PE 7.41
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $15.47
Previous Close $15.64
Change ($) -0.17
Change (%) -1.09%
Day's Open 15.56
Day's Range 15.15 - 16.20
Day's Volume 105,100
52-Week Range 14.85 - 54.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

1 month ago - GlobeNewsWire

The FDA has designated Orphan Drug Status to Sigilon Therapeutics Inc's (NASDAQ: SGTX) SIG-007 to treat Fabry disease. It is a rare genetic disorder caused by AGAL deficiency and the accumulation of spe...

1 month ago - Benzinga

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, FHTX, KLDO, MCRB ...
1 month ago - PRNewsWire

CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

3 months ago - GlobeNewsWire

Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patients...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...

4 months ago - GlobeNewsWire

About SGTX

Sigilon Therapeutics is a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. We have developed our Shielded Living Therapeutics, or SLTx, platform, which combines advanced cell engineering with cutting-edge innovations in biocompatible materials and enables our product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as p... [Read more...]

Industry
Biotechnology
IPO Date
Dec 4, 2020
CEO
Rogerio Vivaldi Coelho
Employees
99
Stock Exchange
NASDAQ
Ticker Symbol
SGTX
Full Company Profile

Financial Performance

In 2020, SGTX's revenue was $13.37 million, a decrease of -5.52% compared to the previous year's $14.16 million. Losses were -$54.61 million, 24.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 50.25, which is an increase of 224.82% from the latest price.

Price Target
$50.25
(224.82% upside)
Analyst Consensus: Buy